AUS Peptide Supply

The early access event

Black
Friday.

20%OFF

Storewide. Starting now.

Early Black Friday

Your favourites.
An earlier saving.

Get 20% off all APS products. Sale prices are already applied, so you can get straight to shopping.

  • No discount code needed
  • Stacks with volume savings
  • Save up to 32% on eligible quantities
Shop the sale

APS products only. Partner offers excluded. Shipping and payment fees calculated at checkout.

The Research Journal.Peptide science, in perspective.
Evidence dossierPublished Updated Version 1.0

5-Amino-1MQ research guide

Small-molecule NNMT inhibitor; quinolinium compound

A guide to 5-Amino-1MQ identity, NNMT enzyme studies and mouse evidence, with chemical form and labelled mass kept separate from measured sample properties.

AUS Peptide Supply editorial team
5-amino-1-methylquinolinium5A1MQ

01 · Identity

What the name identifies

5-Amino-1MQ refers to 5-amino-1-methylquinolinium, a small molecule investigated as an inhibitor of nicotinamide N-methyltransferase (NNMT). It is not a peptide. NNMT is an enzyme involved in nicotinamide methylation; an NNMT inhibitor is a different experimental material from NAD+ or a NAD+ precursor. The exact salt and counterion of the APS catalogue material are unconfirmed, so no formulation-specific molecular weight, formula or CAS number is assigned here.

02 · Evidence position

What the literature can support

The cited studies use biochemical assays, cultured cells and diet-induced-obese mice. They support investigating the target and compound in those systems. They do not establish a human benefit or identify the chemical form in a commercial powder. Read which compound, salt, assay and endpoint was used before comparing findings or quantities.

03 · Study-level map

Evidence and its limits

Preclinical

How was NNMT inhibition investigated?

The 2018 study profiled a series of small molecules using permeability and enzyme-selectivity assays, then examined 5-amino-1MQ-related effects in cultured adipocytes and diet-induced-obese mice. The experiments included NNMT reaction-product and metabolic measurements.

Limit: Cellular and mouse observations are not human efficacy data. Results depend on the studied compound and experimental conditions, not simply the NNMT inhibitor label.

Preclinical

What did the later mouse study measure?

The 2024 study assessed 5A1MQ in diet-induced-obese mice over 28 days, including body composition, glucose-related variables, liver histology and compound distribution. It reported less weight and fat-mass gain and changes in metabolic and liver endpoints.

Limit: These outcomes were measured in an animal model. They do not establish the effects of a different preparation or support a human-use protocol.

04 · Analytical context

Questions a batch record should answer

  1. 01What exact chemical form and counterion are supplied, and does the stated quantity refer to that form or another defined basis?
  2. 02Which identity measurements and quantitative content results support the material specification, separately from an area-purity percentage?
  3. 03Can any tested sample be traced to the offered lot, and are relevant impurities, water or residual-solvent measurements reported when required by the method?

05 · Boundary conditions

What this record does not establish

  • The APS 50mg label does not resolve the unknown salt or counterion; a molar comparison cannot be assumed from the short name.
  • No matching APS analytical report for this presentation was verified for this guide.
  • The selected preclinical papers do not establish human efficacy, a general safety profile or the properties of current supplier inventory.

Sources checked

  1. 1.
    Small-molecule NNMT inhibitors in cell assays and obese mice

    Neelakantan et al. — Biochemical Pharmacology · 2018 · Primary study

  2. 2.
    5A1MQ and metabolic endpoints in diet-induced-obese mice

    Babula et al. — Diabetes, Obesity and Metabolism · 2024 · Primary study

Continue through the topic